Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...
Like many health plans, Lilla’s insurance didn’t cover Wegovy for weight loss use. Out of pocket, a month’s supply came with a price tag of more than $1,300. Even after applying a coupon from the drug ...
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...
The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related semaglutide-based drugs, Ozempic and Wegovy – since 2022 amid unprecedented ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...
High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA ...
The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...
The new structure includes the creation of a unified Human Foods Program, the adoption of a new model for the FDA's field operations and will mean more inspections for CPGs, according to experts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback